Home sleep diagnostics maker receives funding
By HME News Staff
Updated 9:40 AM CST, Thu November 16, 2023
NAMEN, Belgium – Sunrise, which has developed a chin sensor that monitors mandibular jaw movements to diagnose sleep disorders, has received an aggregate investment of $6 million from the Alexa Fund and French health care investor UI-Investissement (Majycc Innovation Santé) for a total of $24 million raised this year. “Sleep disorders are a global concern, and we're proud to be an investor in Sunrise and support their innovative approach to aid in the diagnosis of sleep-related breathing disorders," said Paul Bernard, director of the Alexa Fund. "Their technology, designed for multi-night testing that leverages key sleep metrics, has the potential to redefine sleep apnea diagnosis and care for millions of people suffering from sleep disorders worldwide." The new funding enables Sunrise to further expand its reach, making quality sleep diagnostics more accessible and personalized. Sunrise has received two approvals from the U.S. Food and Drug Administration, a renewed CE certification under MDR1 in Europe and the 2022 SleepTech Award from the American National Sleep Foundation.
Comments